Day One Biopharmaceuticals (DAWN) Price & Analysis

Compare

348 Followers

DAWN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$5.64 - $16.76

Previous CloseN/A

Volume175.11K

Average Volume (3M)1.79M

Market Cap

$628.93M

Enterprise Value$219.85M

Total Cash (Recent Filing)$453.10M

Total Debt (Recent Filing)$3.00M

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Nov 10, 2025

EPS Estimate

-0.29

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.29

Shares Outstanding102,431,930

10 Day Avg. Volume2,791,445

30 Day Avg. Volume1,785,328

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.35

Enterprise Value/Revenue1.17

Enterprise Value/Gross Profit1.25

Enterprise Value/Ebitda-2.00

Forecast

1Y Price Target

$22.67

Price Target Upside265.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Financial PerformanceDay One Biopharmaceuticals reported a robust cash position of $453.1MN, a best-in-class commercial product, and an experienced management, making it a buying opportunity.

Market AdoptionOjemda quarterly prescriptions increased by 15%, with over 3,300 total prescriptions written in the US, highlighting strong adoption.

Product GrowthSteady growth is assumed for Ojemda with peak sales of over $500 million in the US.

Bears Say

EarningsThe 2Q25 EPS of -$0.29, while slightly higher than consensus, reflects a challenging financial performance.

Revenue GuidanceThe FY 2025 product net revenue guidance of $140M - $150M is lower than the consensus of $151.7M.

Sales PerformanceOjemda sales of $33.9M came in approximately 4.5% lower than consensus expectations.

Day One Biopharmaceuticals News

Day One Biopharmaceuticals price target lowered to $17 from $20 at BofA

BofA lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $17 from $20 and keeps a...

9d ago

DAWN

Day One price target lowered to $25 from $36 at H.C. Wainwright

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $25 from...

9d ago

DAWN

Day One Biopharmaceuticals reports Q2 EPS (29c), consensus (34c)

Reports Q2 revenue $33.91M, consensus $34.9M. “We have strong momentum going into the second half of 2025. We...

10d ago

DAWN

Promising Growth and Stability Drive Buy Rating for Day One Biopharmaceuticals

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on DAWN stock, giving a Buy rating on...

4d ago

DAWN

Day One Biopharma’s Earnings Call Highlights Growth and Strategy

Day One Biopharmaceuticals, Inc. (($DAWN)) has held its Q2 earnings call. Read on for the main highlights of...

8d ago

DAWN

Promising Growth and Strategic Innovation Drive Buy Rating for Day One Biopharmaceuticals

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Day One Biopharmaceuticals and decreased the...

9d ago

DAWN

Buy Rating for Day One Biopharmaceuticals Amid Promising Future Catalysts Despite Current Challenges

Day One Biopharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ami Fadia...

9d ago

DAWN

Day One Biopharma Reports Strong Q2 2025 Growth

Day One Biopharmaceuticals, Inc. ( ($DAWN) ) has released its Q2 earnings. Here is a breakdown of the...

9d ago

DAWN

Day One Biopharmaceuticals Reports Strong Q2 2025 Results

Day One Biopharmaceuticals ( ($DAWN) ) just unveiled an update. On August 5, 2025, Day One Biopharmaceuticals reported...

10d ago

DAWN

Day One Biopharmaceuticals appoints Michael Vasconcelles as Head of R&D

Day One Biopharmaceuticals (DAWN) announced that Michael Vasconcelles, M.D., has joined the Company as Head of Research &...

2M ago

DAWN

Day One Biopharmaceuticals Approves Key Proposals at Annual Meeting

Day One Biopharmaceuticals ( ($DAWN) ) just unveiled an announcement. On June 2, 2025, Day One Biopharmaceuticals held...

2M ago

DAWN

Positive Outlook for Day One Biopharmaceuticals’ Ojemda: A Promising First-Line Treatment for Pediatric Glioma

Analyst Soumit Roy of JonesTrading maintained a Buy rating on Day One Biopharmaceuticals (DAWN – Research Report), retaining...

2M ago

DAWN

Buy Rating for Day One Biopharmaceuticals Driven by FDA Approval and Strong Market Potential

Analyst Andres Y. Maldonado of H.C. Wainwright maintained a Buy rating on Day One Biopharmaceuticals (DAWN – Research...

2M ago

DAWN

Promising Future for Day One Biopharmaceuticals: Buy Rating on Ojemda’s Potential in Pediatric Brain Tumors

J.P. Morgan analyst Anupam Rama maintained a Buy rating on Day One Biopharmaceuticals (DAWN – Research Report) today...

2M ago

DAWN

DAWN FAQ

What was Day One Biopharmaceuticals’s price range in the past 12 months?

Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $16.76 in the past 12 months.

What is Day One Biopharmaceuticals’s market cap?

Day One Biopharmaceuticals’s market cap is $628.93M.

When is Day One Biopharmaceuticals’s upcoming earnings report date?

Day One Biopharmaceuticals’s upcoming earnings report date is Nov 10, 2025 which is in 87 days.

How were Day One Biopharmaceuticals’s earnings last quarter?

Day One Biopharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.357 by $0.067.

Is Day One Biopharmaceuticals overvalued?

According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Day One Biopharmaceuticals pay dividends?

Day One Biopharmaceuticals does not currently pay dividends.

What is Day One Biopharmaceuticals’s EPS estimate?

Day One Biopharmaceuticals’s EPS estimate is -0.29.

How many shares outstanding does Day One Biopharmaceuticals have?

Day One Biopharmaceuticals has 102,431,930 shares outstanding.

What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?

Day One Biopharmaceuticals reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.357. Following the earnings report the stock price went down -15.698%.

Which hedge fund is a major shareholder of Day One Biopharmaceuticals?

Currently, no hedge funds are holding shares in DAWN

Day One Biopharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-24.75%

Trailing 12-Months

Asset Growth

29.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Day One Biopharmaceuticals

Day One Biopharmaceuticals (DAWN) is a clinical-stage biopharmaceutical company that focuses on developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. The company is dedicated to advancing innovative oncology treatments with an emphasis on improving the lives of children and adults living with cancer.

Day One Biopharmaceuticals (DAWN) Earnings & Revenues

Historic Earnings Reports

DAWN Company Deck

DAWN Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflected a predominantly positive outlook with strong financial performance driven by OJEMDA's commercial success and strategic guidance for 2025. While there were some challenges, such as the discontinuation of the VRK1 program and rash management issues, the company's financial health and research developments indicate a solid foundation for future growth.View all DAWN earnings summaries

DAWN Stock 12 Month Forecast

Average Price Target

$22.67

▲(265.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","20":"$20","35":"$35","12.5":"$12.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$34.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.5,20,27.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,8.753846153846155,10.857692307692307,12.961538461538462,15.065384615384616,17.169230769230772,19.27307692307692,21.376923076923077,23.480769230769234,25.584615384615383,27.68846153846154,29.792307692307695,31.896153846153844,{"y":34,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,7.882307692307693,9.114615384615385,10.346923076923078,11.57923076923077,12.811538461538463,14.043846153846156,15.276153846153848,16.50846153846154,17.74076923076923,18.973076923076924,20.205384615384617,21.43769230769231,{"y":22.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.65,7.36923076923077,8.088461538461539,8.807692307692308,9.526923076923078,10.246153846153847,10.965384615384615,11.684615384615384,12.403846153846153,13.123076923076923,13.842307692307692,14.561538461538461,15.28076923076923,{"y":16,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.17,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.65,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.37,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.06,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.61,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.01,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >